Release Date: January 7, 2026
Expiration Date: January 7, 2027
Activity Overview
Asparaginase is the cornerstone of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) treatment, which generally includes combination treatment with chemotherapy and radiotherapy. Although general principles of ALL/LBL treatment have emerged and are followed in most cancer treatment centers, identifying immunogenic reactions, optimizing therapeutic drug monitoring, and switching between asparaginase preparations are among the many challenges practitioners face when managing adolescent, young adult, and adult patients with ALL/LBL.
This symposium features our Cases & Conversations™ format, in which 3 clinical experts use case-based discussions to highlight clinically relevant aspects of using asparaginase formulations for ALL/LBL. This engaging format is designed to help clinicians identify best clinical practices regarding selecting asparaginase therapy, monitoring for adverse events, and using multidisciplinary strategies to improve outcomes for their patients with ALL/LBL.
This educational activity is an archive of the live presentation held on December 5, 2025.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This educational activity is directed toward physicians, nurses, nurse practitioners, physician assistants, pharmacists, and other health care providers involved in the diagnosis and treatment of ALL/LBL.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Utilize current best practices to monitor and manage adverse events (AEs) and toxicities associated with various asparaginase formulations for ALL/LBL
- Examine current data and ongoing clinical trials on approved and emerging asparaginase formulations for ALL/LBL
- Identify patients with ALL/LBL who should be switched to an alternative asparaginase formulation upon the development of hypersensitivity or silent inactivation
- Apply multidisciplinary strategies to address asparaginase-associated AEs and toxicities, including distinguishing between hypersensitivity reactions and infusion reactions
Daniel J. DeAngelo, MD, PhD
Chief, Division of Leukemia
Department of Medical Oncology
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, MA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Amgen, Autolus, Blueprint, Incyte, Jazz, Novartis, Pfizer, Servier, Takeda; Grant/Research Funding (to institution): Abbvie, Blueprint, Glyomimetrics, Novartis; Other: DSMB: Daiichi Sankyo, DSMB: Mount Sinai MPN Consortium
Shira Dinner, MD
Associate Professor
Northwestern University
Robert H. Lurie Comprehensive Cancer Center
Executive Officer, Alliance for Clinical Trials
Chicago, IL
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Amgen, Autolus, Cycle, Enliven; Grant/Research Funding: AstraZeneca, Cellectis
Stephen P. Hunger, MD
Jeffrey E. Perelman Distinguished Chair in Pediatrics
Chief, Division of Pediatric Oncology
Director, Center for Childhood Cancer Research
Children’s Hospital of Philadelphia
Philadelphia, PA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Jazz, Servier; Ownership interests in publicly traded companies: Amgen common stock
Jae H. Park, MD
Chief, Cellular Therapy Service
Attending Physician
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Adaptive Biotech, Allogene, Amgen, Artiva, Autolus, Beigne, Bright Pharma, Caribou, Curocell, Galapagos, Iovance, Jazz Pharmaceuticals, Kite, Novartis, Pfizer, Servier, Sobi, Synthekine, Takeda
Full faculty information and disclosures are available by reviewing the program workbook, linked here.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC (PER®) have no relevant financial relationships with ineligible companies.
PER mitigated all COI for faculty, staff, and planners prior to the start of this activity.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here